Biotech Dynavax Technologies (NASDAQ:DVAX) soared Thursday, even as the market overall crashed, after its hepatitis B vaccine beat GlaxoSmithKline's (NYSE:GSK) standard product in a late-stage clinical trial.
Dynavax said that its vaccine, Hepislav-B, showed a 95.4% rate of peak seroprotection, in contrast with only 81.3% for Glaxo's Engerix-B. Dynavax focused especially on patients with diabetes mellitus, who don't respond well to current vaccines and treatments. In the study, the seroprotection rate for Hepislav-B was 90%, as opposed to Engerix-B's 65.1%.
The study also showed that the two vaccines had similar safety profiles. A number of adverse events occurred in both arms, mostly autoimmune-related, but Dynavax said that they were not related to vaccinations.
Labels: Biotech Dnyavax, Glaxo, HBV vaccine